My Cart

SOST

SOST Overview

English NameSclerostinApproved Drugs1
Drugs in Clinical Trials6Target SynonymSclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
Highest Development StageApproved
English NameSclerostin
Target SynonymSclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
Approved Drugs1
Drugs in Clinical Trials6
Highest Development StageApproved

SOST Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (2)

  • Tag

    His Tag (2)

  • Conjugate

    Unconjugated (1)Biotin-labeled (1)

SOST Background

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

SOST Synonyms

SOST,VBCH

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
SetrusumabUX143; NOV-3; MOR-05813; BPS-804Phase 3 ClinicalMorphosys Ag, Novartis Pharma AgBone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Osteoporosis; Renal Insufficiency, Chronic
Details
AGA-2115AGA2115; AGA-2115Phase 2 ClinicalAngitia Biopharmaceuticals (Guangzhou) LtdOsteogenesis Imperfecta
Details
AGA-2118AGA-2118Phase 2 ClinicalAngitia Biomedicines LtdOsteoporosis; Osteoporosis, Postmenopausal
Details
ResugosbartSHR-1222Phase 1 ClinicalJiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co LtdOsteoporosis; Osteoporosis, Postmenopausal
Details
Romosozumab biosimilar(Zhuhai Federation Biomedicine)Phase 1 ClinicalZhuhai Federation Biomedicine Co LtdOsteoporosis, Postmenopausal
Details
BlosozumabTST002; LY-2541546; TST002-IgG4Phase 1 ClinicalEli Lilly And CompanyOsteoporosis; Osteoporosis, Postmenopausal
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
RomosozumabCDP-7851; AMG-785ApprovedEvenity, EVENITYJapanOsteoporosisAmgen Inc2019-01-08Bone Diseases, Metabolic; Fractures, Bone; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis, Postmenopausal
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland